4.19
-0.155(-3.57%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.25 |
| Day High | 4.36 |
| Day Low | 4.14 |
| 52-Week High | 17 |
| 52-Week Low | 2.68 |
| Volume | 857,686 |
| Average Volume | 10.09M |
| Market Cap | 326.76M |
| PE | -1.29 |
| EPS | -3.24 |
| Moving Average 50 Days | 5.29 |
| Moving Average 200 Days | 9.37 |
| Change | -0.15 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $276.06 as of September 30, 2025 at a share price of $4.185. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $181.8 as of September 30, 2025 at a share price of $4.185.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune Provides Update Following Type A Meeting with FDA
GlobeNewswire Inc.
Sep 18, 2025 1:15 PM GMT
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meetin
Replimune Announces Type A Meeting Scheduled with FDA
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food a
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Jul 22, 2025 11:00 AM GMT
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration